U.S. National Institutes of Health
U.S. National Institutes of Health


IDRankTitleRecruitmentStudy ResultsConditionsInterventionsURL
176011176011Complications and Adverse Effects in Continuous Peripheral Regional AnesthesiaCompletedNo Results AvailableInfection|Inflammation|Adverse EffectsProcedure: perineural block (anesthesia)https://ClinicalTrials.gov/show/NCT00251654
176012176012The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED)CompletedHas ResultsPsoriasisDrug: infliximab|Drug: methotrexatehttps://ClinicalTrials.gov/show/NCT00251641
176013176013Home Care Management of Pediatric PainCompletedNo Results AvailableTonsillectomyOther: Standard Care|Other: ATC Dosing|Other: Structured Pain Management Program|Other: As needed dosinghttps://ClinicalTrials.gov/show/NCT00251628
176014176014Calcium Channel Splice Variant Expression in Cardiovascular Disease and AgingCompletedNo Results AvailableAtherosclerosishttps://ClinicalTrials.gov/show/NCT00251615
176015176015Analysis of Atropine and Propranolol Induced ChangesCompletedNo Results AvailableHealthyDrug: Atropine|Drug: Propranolol|Drug: Normal Salinehttps://ClinicalTrials.gov/show/NCT00251602
176016176016A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)TerminatedHas ResultsCarcinoma, Non-Small-Cell LungDrug: Vorinostat|Drug: Vorinostat|Drug: Vorinostat|Drug: Vorinostat|Drug: erlotinibhttps://ClinicalTrials.gov/show/NCT00251589
176017176017Aggrastat to Zocor (AtoZ) - the Use of Two Approved Drugs to Treat Patients Who Have Experienced Chest Pain or a Heart Attack (0733-180)CompletedNo Results AvailableAcute Coronary SyndromeDrug: A-Phase: tirofiban; Z-Phase simvastatin|Drug: Duration of Treatment: A-Phase: minimum suggested 48 hours, maximum suggested 108 hours. Z-Phase: 2 years|Drug: Comparator: A-Phase: low molecular weight heparin, unfractionated heparin|Drug: Duration of Treatment: A-Phase: low molecular weight heparin, 2 to 8 days; unfractionated heparin, minium suggested 48 hours, maximum 108 hours|Drug: Duration of Treatment: Z-Phase, 2 years.https://ClinicalTrials.gov/show/NCT00251576
176018176018Epidemiologic, Laboratory, and Clinical Characterization of Individuals With Cancer.RecruitingNo Results AvailableCancerhttps://ClinicalTrials.gov/show/NCT00251563
176019176019Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural MesotheliomaCompletedNo Results AvailableMalignant Pleural MesotheriomaDrug: Pemetrexed|Drug: Cisplatinhttps://ClinicalTrials.gov/show/NCT00251550
176020176020A Pilot Study of LTB4 in HIV-1 Infected AdultsCompletedNo Results AvailableHIV InfectionsDrug: LTB4https://ClinicalTrials.gov/show/NCT00251537
176021176021A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in Advanced Non-Squamous NSCLCCompletedNo Results AvailableNon-Small Cell Lung CancerDrug: Bevacizumab, Oxaliplatin, Pemetrexedhttps://ClinicalTrials.gov/show/NCT00251524
176022176022A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic SyndromeTerminatedNo Results AvailableMyelodysplastic SyndromeDrug: Arsenic Trioxidehttps://ClinicalTrials.gov/show/NCT00251511
176023176023Phase II Study of Cetuximab in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung CancerCompletedNo Results AvailableCarcinoma, Non-Small-Cell LungDrug: Cetuximabhttps://ClinicalTrials.gov/show/NCT00251498
176024176024A Phase II Trial of Modified FOLFOX 6 and Cetuximab in First Line Treatment of Metastatic Colorectal CancerCompletedNo Results AvailableColorectal CancerDrug: Cetuximabhttps://ClinicalTrials.gov/show/NCT00251485
176025176025A Phase II Trial of Abraxaneâ„¢ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast CancerCompletedNo Results AvailableMetastatic Breast CancerDrug: Paclitaxel Albumin Nanoparticle for Injectable Suspensionhttps://ClinicalTrials.gov/show/NCT00251472
176026176026A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)CompletedNo Results AvailableChoroidal Neovascularization|Age-related Macular DegenerationDrug: rhuFab V2 (ranibizumab)https://ClinicalTrials.gov/show/NCT00251459
176027176027A Phase II Single Arm Trial of Single-agent Vinflunine as Second-line Treatment of Advanced Non-Small Cell Lung CancerCompletedNo Results AvailableNon-Small Cell Lung CancerDrug: Vinfluninehttps://ClinicalTrials.gov/show/NCT00251446
176028176028GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast CancerActive, not recruitingNo Results AvailableNeoplasms, BreastDrug: lapatinib, docetaxel, trastuzumab|Drug: Docetaxel, trastuzumabhttps://ClinicalTrials.gov/show/NCT00251433
176029176029Writing About Disease: Effect on Rehabilitation?CompletedNo Results AvailableCOPD|AsthmaProcedure: writing about diseasehttps://ClinicalTrials.gov/show/NCT00251420
176030176030Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor MalignanciesCompletedNo Results AvailableSolid TumorDrug: Taxotere|Drug: Cisplatin|Drug: CPT-11https://ClinicalTrials.gov/show/NCT00251407
176031176031Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular LymphomaCompletedNo Results AvailableNon-Hodgkin's LymphomaDrug: Rituxan|Drug: 1018 ISShttps://ClinicalTrials.gov/show/NCT00251394
176032176032Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.RecruitingNo Results AvailableOropharyngeal NeoplasmsDrug: Cetuximabhttps://ClinicalTrials.gov/show/NCT00251381
176033176033Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory LeukemiaCompletedNo Results AvailableLeukemia, Myelocytic, Acute|Acute Lymphocytic LeukemiaDrug: 9-Aminocamptothecin (9-AC)https://ClinicalTrials.gov/show/NCT00251368
176034176034Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Non-Metastatic Pancreatic CancerActive, not recruitingNo Results AvailablePancreatic CancerDrug: Gemcitabine|Drug: 5-Fluorouracil|Procedure: Radiation Therapyhttps://ClinicalTrials.gov/show/NCT00251355
176035176035Outcome of Postnatal Depression Screening Using Edinburgh Postnatal Depression ScaleRecruitingNo Results AvailableDepression, PostpartumProcedure: Edinburgh Postnatal Depression Scalehttps://ClinicalTrials.gov/show/NCT00251342
176036176036Docetaxel, Carboplatin, and Capecitabine as Treatment for Patients With Locally Advanced or Inflammatory Breast Cancer Before SurgeryActive, not recruitingNo Results AvailableBreast CancerDrug: neoadjuvant chemotherapyhttps://ClinicalTrials.gov/show/NCT00251329
176037176037Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid CancerCompletedHas ResultsThyroid Cancer|Differentiated Thyroid CarcinomaDrug: Lithium Carbonate|Drug: Placebohttps://ClinicalTrials.gov/show/NCT00251316
176038176038Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum DisordersCompletedHas ResultsObsessive-Compulsive Disorder|Autism Spectrum Disorder|Autism|Asperger Disorder|Developmental DisorderDrug: Riluzole|Drug: Placebohttps://ClinicalTrials.gov/show/NCT00251303
176039176039Diagnosis and Treatment of Sleep-Disordered Breathing in the Homes of Patients With Transient Ischemic AttackCompletedNo Results AvailableTransient Ischemic Attack|Sleep ApneaProcedure: auto-titrating continuous positive airway pressurehttps://ClinicalTrials.gov/show/NCT00251290
176040176040Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic PurpuraWithdrawnNo Results AvailableThrombotic Thrombocytopenic PurpuraDrug: Rituximabhttps://ClinicalTrials.gov/show/NCT00251277

* Görseller ve İçerik tekif hakkına sahip olabilir